Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Posts Strong Revenue Growth, R&D Spending in Q3

NEW YORK, Nov. 1 - Ciphergen Biosystems yesterday reported nearly two-fold growth in revenues and R&D spending during the third quarter amid a slightly widened net loss.

 

Revenues for the period ended Sept. 30 swelled to $10.2 million from $5.4 million one year ago.

 

R&D spending mirrored the revenue increase, jumping to $6.0 million from $3.3 million in the third quarter 2001.

 

As a result, net loss widened to $7.9 million, or $.29, from $6.9 million, or $.26, year over year, Ciphergen said.

 

The company said it had $51.6 million a year in cash, cash equivalents, and investments in securities as of Sept. 30.

 

Click here for more information.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.